Zobrazeno 1 - 10
of 65
pro vyhledávání: ''
Autor:
Ulrich Jaeger, Marek Borsky, Jan Oppelt, Laura Z. Rassenti, Medhat Shehata, Václav Šeda, Thomas J. Kipps, Gabriela Pavlasova, Jennifer R. Brown, Daniel Filip, Kvetoslava Liskova, Šárka Pospíšilová, Eva Vojackova, Lenka Kostalova, Matthew S. Davids, Marek Mráz, Katerina Cerna, Sonali Sharma, Jiri Mayer, Andrea Janíková, Pedro Faria Zeni, Stacey M. Fernandes, Veronika Šandová, Laura Ondrisova, Michael Doubek, Leos Kren
Publikováno v:
Blood
B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interacti
Autor:
Ester B. M. Remmerswaal, Arnon P. Kater, Iris de Weerdt, Ineke J. M. ten Berge, Tom Hofland, Perry D. Moerland, Nora Liu, Laura M. Faber, Roeland Lameris, Mark-David Levin, Mario van der Stelt, Sanne Endstra, Sanne H. Tonino, Hans van Vliet, Aldo Jongejan, Renée C.G. de Bruin, Eric Eldering, Tanja D. de Gruijl
Publikováno v:
Blood
de Weerdt, I, Hofland, T, Lameris, R, Endstra, S, Jongejan, A, Moerland, P D, de Bruin, R C G, Remmerswaal, E B M, Ten Berge, I J M, Liu, N, van der Stelt, M, Faber, L M, Levin, M-D, Eldering, E, Tonino, S H, de Gruijl, T D, van der Vliet, H J & Kater, A P 2018, ' Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib ', Blood, vol. 132, no. 21, pp. 2260-2272 . https://doi.org/10.1182/blood-2017-12-822569
Blood, 132(21), 2260-2272
Blood, 132(21), 2260-2272. American Society of Hematology
de Weerdt, I, Hofland, T, Lameris, R, Endstra, S, Jongejan, A, Moerland, P D, de Bruin, R C G, Remmerswaal, E B M, Ten Berge, I J M, Liu, N, van der Stelt, M, Faber, L M, Levin, M-D, Eldering, E, Tonino, S H, de Gruijl, T D, van der Vliet, H J & Kater, A P 2018, ' Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib ', Blood, vol. 132, no. 21, pp. 2260-2272 . https://doi.org/10.1182/blood-2017-12-822569
Blood, 132(21), 2260-2272
Blood, 132(21), 2260-2272. American Society of Hematology
The efficacy of autologous (αβ) T-cell–based treatment strategies in chronic lymphocytic leukemia (CLL) has been modest. The Vγ9Vδ2-T cell subset consists of cytotoxic T lymphocytes with potent antilymphoma activity via a major histocompatibili
Autor:
Guy Sauvageau, Josée Hébert, Caroline Pabst, Cynthia J. Guidos, Sébastien Lemieux, Isabel Boivin, Geneviève Boucher, Jana Krosl, Vincent-Philippe Lavallée, Sylvain Meloche, Patrick Gendron, Anne Marinier
Publikováno v:
Blood. 127:3054-3061
In this study, we analyzed RNA-sequencing data of 14 samples characterized by biallelic CEBPA (CEBPA(bi)) mutations included in the Leucegene collection of 415 primary acute myeloid leukemia (AML) specimens, and describe for the first time high frequ
Autor:
David J. Inwards, Patrick B. Johnston, Betsy LaPlant, Luis F. Porrata, Han W. Tun, Thomas M. Habermann, Grzegorz S. Nowakowski, Joseph P. Colgan, Svetomir N. Markovic, Mamta Gupta, Stephen M. Ansell, William R. Macon, Ivana N. Micallef, Thomas E. Witzig, Mary Stenson, Jing Jing Han, Craig B. Reeder
Publikováno v:
Blood. 126:328-335
Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in
Autor:
Wolfgang R. Sperr, Susanne Herndlhofer, Tessa L. Holyoake, Katharina Blatt, Christine Mannhalter, Sabine Cerny-Reiterer, Michael Willmann, Thomas Rülicke, Gregor Hoermann, Gabriele Stefanzl, Irina Sadovnik, Peter Valent, Matthias Mayerhofer, Harald Herrmann, Martin Bilban, Berthold Streubel
Publikováno v:
Blood. 123:3951-3962
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion
Autor:
Ya-Huei Kuo, Ravi Bhatia, Hongjun Liu, Yin Wei Ho, Tinisha McDonald, Stephen J. Forman, Cedric Dos Santos, Allen Lin
Publikováno v:
Blood. 122:1900-1913
The SRC family kinases (SFKs) and the receptor tyrosine kinase c-Kit are activated in human acute myeloid leukemia (AML) cells. We show here that the SFKs LYN, HCK, or FGR are overexpressed and activated in AML progenitor cells. Treatment with the SF
Autor:
Kristian M. Bowles, Lyubov Zaitseva, Niraj M. Shah, David J. MacEwan, Stuart A. Rushworth, Megan Y. Murray
Publikováno v:
Blood. 120:5188-5198
NF-E2–related factor 2 (Nrf2) transcription factor regulates a range of cytoprotective transcriptional responses, preventing further cellular injury by removing biochemical damage and renewing tissue. Here we show that acute myeloid leukemia (AML)
Autor:
Serge Fichelson, François Guilhot, Michael W. Melkus, Marie-Claude Meunier, Marie-Laure Bonnet, Angelina Bertrand, Annelise Bennaceur-Griscelli, Jean-Claude Chomel, Ali G. Turhan, Nathalie Sorel
Publikováno v:
Blood. 118:3657-3660
Sustained undetectable molecular residual disease (UMRD) is obtained in a minority of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. It remains unclear whether these patients are definitively cured of their leukemia o
Publikováno v:
Blood. 117:3826-3835
Sézary syndrome (SS) is an aggressive subtype of cutaneous T-cell lymphoma that is characterized by circulating leukemic Sézary cells. The accumulation of these malignant cells has been shown to be the result of the resistance to apoptosis, in part
Autor:
Silvia Xargay-Torrent, Laia Rosich, Patricia Pérez-Galán, Ana Mozos, Emmanuel Normant, Mónica López-Guerra, Ifigènia Saborit-Villarroya, Elias Campo, Dolors Colomer, Gaël Roué
Publikováno v:
Blood. 117:1270-1279
Despite the promising introduction of the proteasome inhibitor bortezomib in the treatment of mantle cell lymphoma (MCL), not all patients respond, and resistance often appears after initial treatment. By analyzing a set of 18 MCL samples, including